Recently, the "2025 China Top Sci-Tech Innovation Companies (Innovative Medical Track)" list, jointly released by China Business Network (CBN) and STAR Market Daily, was officially announced. Two innovative medical enterprises directly invested by Nanjing Innovation Investment Group—NanoVoxel and Tuodao Medical—were successfully selected, ranking among the first echelon of domestic innovative medical enterprises with their innovative strength.

This "2025 China Top Sci-Tech Innovation Companies" list for the innovative medical track focuses on core dimensions such as technological breakthroughs, commercial implementation, and clinical value. It aims to select high-quality enterprises with the greatest growth potential in the industry, serving as a "touchstone of strength" in the field of innovative medicine.

In August this year, Nanjing Innovation Investment Group participated in the investment of hundreds of millions of RMB in NanoVoxel through the urban-rural joint SPV via the Nanjing Major Project Fund under its management. Since the investment, the Group has provided post-investment services such as industrial resource connection and clinical cooperation chain construction to help the enterprise accelerate clinical trials and commercialization processes. As the world's first enterprise to achieve the implementation of static CT products, NanoVoxel focuses on high-speed and high-precision radiation imaging technology. Its "Compound Eye" series static CT adopts a slip-ring-free multi-source architecture, breaking through the physical limits of traditional CT: it improves spatial resolution by 64 times, temporal resolution by 10 times, and reduces radiation dose by 40%, enabling real-time organ imaging and in vivo observation of fine human structures. The company has achieved full-chain independent R&D from photon stream detectors to whole-machine assembly, breaking the monopoly of overseas brands in high-end CT equipment.

In December this year, Nanjing Innovation Investment Group invested over RMB 100 million in Tuodao Medical through the Nanjing Advanced Manufacturing Master Fund and Scenario Fund under its management. Rooted in Nanjing, Tuodao Medical is one of the few domestic enterprises that have achieved a multi-track surgical robot layout. With data algorithms and artificial intelligence at its core, it covers five major tracks including orthopedics, laparoscopy, and percutaneous puncture. It has obtained approval for the production of multiple products such as Tuoshou® Orthopedic Robot and Tuoling® Laparoscopic Robot, among which Tuoling® Laparoscopic Robot was selected as a 2025 Jiangsu Province "Three Firsts and Two News" technical product. Tuodao Medical not only covers multi-department surgical procedures with its products but also builds remote smart medical centers to promote the sinking of high-quality medical resources.

Nanjing Innovation Investment Group focuses on strategic emerging tracks such as hard technology and innovative medicine, deeply exploring innovative enterprises with core technological barriers. In the future, the Group will continue to inject capital momentum and industrial resources into high-quality sci-tech innovation enterprises, helping more "innovation vanguards" grow into industry benchmarks, and promoting the transformation of core technologies into people's livelihood benefits through capital strength.